FDA APPROVES VIREAD® FOR CHRONIC HEPATITIS B
Leading Cause of Liver Cancer Affects 2 Million People in United States

The FDA has approved Viread® (tenofovir disoproxil fumarate) as a new treatment option for adults with chronic hepatitis B, a serious liver disease. Chronic hepatitis B affects an estimated 2 million people in the United States and is the leading cause of liver cancer worldwide.

For important safety information and full prescribing information, please visit www.Viread.com.

Full B-roll

Sound bites include:

  • Fred Poordad, MD / Chief of Hepatology, Cedars-Sinai Center for Liver Disease and Transplantation, Los Angeles
  • Danny Chu, MD / Community Physician, Chinatown, New York City
  • Fiona Ma / Hepatitis B patient, California Assemblywoman, San Francisco

Manufacturing Footage

Viread packaging and manufacturing footage

Research and Lab Footage

Gilead scientific research and lab footage

Hi-Res Photo

Viread bottle

Graphic

Bar chart of estimated chronic hepatitis B prevalence by ethnicity

Related Document

Timeline – Hepatitis Milestones

Video Provided By: "Gilead Sciences"

Click here for more broadcast video & audio news releases and other source material from PR Newswire.

Send Feedback

 Assets For This Story

  Hardcopy Request

NOTE: All requests received before 5:00PM Eastern Time are shipped next day delivery (10:30 AM) unless otherwise specified. If you need faster turnaround time, please call 1-800-653-5313 option 2 and we can make the appropriate arrangements.

 Please submit the following information.
First Name: *
Last Name: *
Station Call Letters: *
Address 1: *
Address 2:
City: *
State: *
Zip: *
Phone Number: *
(Required by overnight delivery carrier)
Email Address: *
Delivery Time: *
Comments:
 
  * Required field.

  Additional Documents

Download the following materials for this News Package:

Use the icons above for more information or call MultiVu Media Relations at 1-800-653-5313 Option 3 or e-mail us or click here for help.